Richard Scott Struthers - 05 Apr 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
05 Apr 2022
Transactions value $
-$541,225
Form type
4
Filing time
07 Apr 2022, 17:58:19 UTC
Previous filing
02 Mar 2022
Next filing
15 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$541K -21.4K -2.4% $25.34 869K 05 Apr 2022 By Family Trust 1 F1, F2
holding CRNX Common Stock 57.4K 05 Apr 2022 Direct
holding CRNX Common Stock 1K 05 Apr 2022 By Spouse
holding CRNX Common Stock 90K 05 Apr 2022 By Family Trust 2
holding CRNX Common Stock 90K 05 Apr 2022 By Family Trust 3
holding CRNX Common Stock 90K 05 Apr 2022 By Family Trust 4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $25.3418 per share. The range of actual sales prices on the transaction date was $25.00 to $25.57 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.